Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
Kunal Jha, Rishav Adhikari, Erfan Tasdighi, Ngozi Osuji, Tanuja Rajan, Michael J. Blaha
Topics & Concepts
MedicineType 2 diabetesGlycemicStroke (engine)Diabetes mellitusAngiologyIntensive care medicineClinical trialCoronary artery diseaseDiseaseInternal medicineKidney diseaseWeight lossAtherosclerotic cardiovascular diseaseObesityCardiologyEndocrinologyMechanical engineeringEngineeringDiabetes Treatment and ManagementDiabetes Management and ResearchMetabolism, Diabetes, and Cancer